Skip to content

Randomized control trial on the effectiveness of Simotang oral liquid in promoting gastrointestinal function recovery after abdominal surgery under accelerated rehabilitation surgery mode

Randomized control trial on the effectiveness of Simotang oral liquid in promoting gastrointestinal function recovery after abdominal surgery under accelerated rehabilitation surgery mode

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065942
Enrollment
Unknown
Registered
2022-11-18
Start date
2022-11-18
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal dysfunction after abdominal surgery

Interventions

Postoperative test group of benign diseases related to uterus and accessories:Perioperative management measures for accelerated rehabilitation surgery + Simotang oral liquid
Postoperative control group of benign diseases related to uterus and accessories:Perioperative management measures of accelerated rehabilitation surgery + HouPuPaiQiHeJi
Colon cancer and colon surgery group:Perioperative management measures for accelerated rehabilitation surgery + Simotang oral liquid
Population control group after colon surgery for colon cancer:Perioperative management measures of accelerated rehabilitation surgery + HouPuPaiQiHeJi

Sponsors

Jiangsu Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Postoperative inclusion criteria for benign diseases related to uterus and accessories: 1. Postoperative patients with benign uterine and adnexal diseases according to the perioperative management measures of ERAS; 2. The postoperative anesthesia recovery was good and the vital signs were stable; 3. Laparoscopic, vaginal or laparotomy were selected; 4. Operation duration = 18 years; 6. Informed consent and voluntary participation. Inclusion criteria for colon cancer after operation: 1. Postoperative patients with colon cancer who were performed according to the perioperative management measures of ERAS; 2. Select laparoscopic surgery; 3. The postoperative anesthesia recovery was good and the vital signs were stable; 4. Aged >= 18 years; 5. The expected postoperative survival time is >= 6 months; 6. Informed consent and voluntary participation.

Exclusion criteria

Exclusion criteria: Exclusion criteria for benign diseases related to uterus and accessories after operation: 1. Mechanical intestinal obstruction caused by internal hernia, intestinal volvulus, anastomotic stenosis and other factors, or paralytic obstruction and strangulated intestinal obstruction caused by retroperitoneal infection, electrolyte disorder and other reasons after abdominal surgery; 2. Patients with intestinal tumor or uterine malignant tumor; 3. Complicated with serious primary diseases such as heart, liver, kidney, brain, endocrine and hematopoietic system; 4. Those who are allergic to the study drug or have allergic constitution (allergic to two or more substances); 5. Patients who participated in other clinical trials within 1 month before enrollment; 6. The researcher thinks it is inappropriate to participate in this study. Exclusion criteria for colon cancer after operation: 1. Mechanical intestinal obstruction caused by internal hernia, intestinal volvulus, anastomotic stenosis and other factors, or paralytic obstruction and strangulated intestinal obstruction caused by retroperitoneal infection, electrolyte disorder and other reasons after abdominal surgery; 2. Patients undergoing enterostomy transferred to patients after colostomy; 3. Patients with intestinal fistula, intra-abdominal hemorrhage and intra-abdominal infection after colon cancer surgery; 4. Complicated with serious primary diseases such as heart, liver, kidney, brain, endocrine and hematopoietic system; 5. Those who are allergic to the study drug or have allergic constitution (allergic to two or more substances); 6. Patients who participated in other clinical trials within 1 month before enrollment; 7. The researcher thinks it is inappropriate to participate in this study.

Design outcomes

Primary

MeasureTime frame
Time for resuming oral half flow diet and tolerating good condition for 48 hours;

Secondary

MeasureTime frame
Time of first anal exhaust Daily record after operation;Postoperative hospital stay;Proportion of patients who resumed oral half flow diet and had good tolerance for 48 hours;Postoperative Patient Rehabilitation Scale;Therapeutic effect of TCM syndrome (total effective rate, disappearance rate of single symptom);

Countries

China

Contacts

Public ContactJiang Zhiwei

Jiangsu Province Hospital of Chinese Medicine

liuhanfei@zyyjypj.cn+86 13930370172

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026